In a large observational study, SGLT2 inhibitor therapy in ATTR-CM was linked to improved heart failure symptoms, preserved renal function, and a reduced need for diuretics while also significantly lowering the risk of heart failure hospitalization and cardiovascular mortality [83]. Here, SLC5A2 is linked to heart failure.